Two former CSL (ASX:CSL) scientists have joined Nexvet's veterinary biologics research centre in Melbourne.

GSK is calling for Australian and New Zealand researchers and start-up companies to submit ideas for potential partnership opportunities.

A potential new treatment option for bone marrow transplant patients who develop transplant-related chronic graft-versus-host disease will soon be tested in a clinical trial.

The 2014-15 Laboratory Guide to Workplace Safety has been released. [ + ]

The ASI Annual Scientific meeting has joined forces with several clinically oriented societies this year to bring bench and bedside researchers together for one big immunological event. [ + ]

Global Kinetics has been cleared to sell the Australian-made Parkinson's KinetiGraph wearable symptom monitoring device in the US.

Further to the notice of the forthcoming election for AusBiotech's board of directors, nominations are now open for eligible AusBiotech members.

Virax (ASX:VHL) has received a technical assessment that will allow it to start the process of reactivating the US IND application for cancer drug GGTI-2418.

pSivida (ASX:PVA) licensee Alimera Sciences has got the marketing nod in Sweden for DMO treatment Iluvien, marking its 10th EU approval.

The 2014 Australian Museum Eureka Prize winners were announced at an award dinner held last night at Sydney Town Hall. The national awards, which have been running since 1990, acknowledge outstanding contributions to Australian science. [ + ]

Pharmaxis' (ASX:PXS) Bronchitol may have missed its main endpoint in last year's bronchiectasis trial, but new analysis shows a statistically significant improvement in high-risk patients. [ + ]

An international research effort into the genome sequencing of the coffee plant has revealed its 'convergent evolution' with unrelated cacao and tea plants.

Patents are at the core of enabling genetic tests, treatments, vaccines and cures resulting from medical research, says AusBiotech - contrary to reports stemming from last week's Federal Court decision in the D'Arcy v Myriad Genetics case that claim research is being stifled.

Ascend Biopharmaceuticals aims to commence a phase II trial of BCC treatment candidate ASN-002 in 1H15 and a phase Ib trial of breast cancer candidate ASN-004 in 2H15.

Professor David Black has been re-elected as Secretary General of the International Council for Science. [ + ]